ALNYLAM PHARMACEUTICALS, INC. (ALNY) Current Ratio
- Current ratio · latest quarter: Value 3.05×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.05× | Current assets / current liabilities. $4.62B ÷ $1.51B ≈ 3.05× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 4.62B USD | Assets, Current |
| Current obligations | 1.51B USD | Liabilities, Current |
| Cash and equivalents | 1.71B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 1.60B USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | 912.74M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 97.11M USD | Inventory, Net |
| Payables | 108.02M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.62B | $1.51B | $1.71B | $1.60B | $912.74M | $97.11M | $108.02M | (m) | 3.05× |
| 2025-12-31 | $4.05B | $1.47B | $1.66B | $1.25B | $777.57M | $82.72M | $115.72M | (m) | 2.76× |
| 2025-09-30 | $3.95B | $1.56B | $1.49B | $1.23B | $964.77M | $75.38M | $117.59M | (m) | 2.54× |
| 2025-06-30 | $3.64B | $1.30B | $1.11B | $1.74B | $567.11M | $71.69M | $102.39M | (m) | 2.80× |
| 2025-03-31 | $3.27B | $1.08B | $1.02B | $1.61B | $418.04M | $65.58M | $97.40M | (m) | 3.04× |
| 2024-12-31 | $3.30B | $1.19B | $966.43M | $1.72B | $405.31M | $78.51M | $88.42M | (m) | 2.78× |
| 2024-09-30 | $3.36B | $1.22B | $1.10B | $1.67B | $353.85M | $75.99M | $70.81M | (m) | 2.75× |
| 2024-06-30 | $3.17B | $1.06B | $968.49M | $1.65B | $309.48M | $83.98M | $73.98M | (m) | 3.01× |
| 2024-03-31 | $2.99B | $941.71M | $681.88M | $1.68B | $321.38M | $93.99M | $78.15M | (m) | 3.17× |
| 2023-12-31 | $2.98B | $967.79M | $812.69M | $1.62B | $327.79M | $89.15M | $55.52M | (m) | 3.08× |
| 2023-09-30 | $2.99B | $949.78M | $1.03B | $1.36B | $325.44M | $95.77M | $73.84M | (m) | 3.14× |
| 2023-06-30 | $2.52B | $788.64M | $657.80M | $1.37B | $220.63M | $100.45M | $59.75M | (m) | 3.20× |
| 2023-03-31 | $2.54B | $673.39M | $672.25M | $1.37B | $219.43M | $131.88M | $62.24M | (m) | 3.77× |
| 2022-12-31 | $2.69B | $767.91M | $866.39M | $1.30B | $237.96M | $128.96M | $98.09M | (m) | 3.51× |
| 2022-09-30 | $2.69B | $772.79M | $1.07B | $1.17B | $184.51M | $115.49M | $40.57M | (m) | 3.48× |
| 2022-06-30 | $2.47B | $657.68M | $575.56M | $1.50B | $142.27M | $88.98M | $52.42M | (m) | 3.76× |
| 2022-03-31 | $2.59B | $605.96M | $534.08M | $1.67B | $156.53M | $78.52M | $54.92M | (m) | 4.27× |
| 2021-12-31 | $2.81B | $695.71M | $819.98M | $1.55B | $198.57M | $86.36M | $73.43M | (m) | 4.04× |
| 2021-09-30 | $2.68B | $610.66M | $1.09B | $1.16B | $141.06M | $97.90M | $40.05M | (m) | 4.38× |
| 2021-06-30 | $2.73B | $554.65M | $745.77M | $1.10B | $146.59M | $84.36M | $53.08M | (m) | 4.91× |
| 2021-03-31 | $2.47B | $494.82M | $379.54M | $1.27B | $110.63M | $73.94M | $45.38M | (m) | 4.99× |
| 2020-12-31 | $2.61B | $585.27M | $496.58M | $1.33B | $102.41M | $75.20M | $51.97M | (m) | 4.47× |
| 2020-09-30 | $2.55B | $480.24M | $496.70M | $1.28B | $79.12M | $66.94M | $27.87M | (m) | 5.32× |
| 2020-06-30 | $2.16B | $384.30M | $580.83M | $1.26B | $69.11M | $77.42M | $26.13M | (m) | 5.62× |
| 2020-03-31 | $1.58B | $338.79M | $467.78M | $836.35M | $75.57M | $68.30M | $40.48M | (m) | 4.68× |
| 2019-12-31 | $1.72B | $352.59M | $547.18M | $975.02M | $43.01M | $56.35M | $49.88M | (m) | 4.87× |
| 2019-09-30 | $1.90B | $352.86M | $923.30M | $797.75M | $48.11M | $54.56M | $39.39M | (m) | 5.38× |
| 2019-06-30 | $2.06B | $328.60M | $1.14B | $790.54M | $30.74M | $40.59M | $71.22M | (m) | 6.28× |
| 2019-03-31 | $1.39B | $149.16M | $724.96M | $519.58M | $33.80M | $32.00M | $22.67M | (m) | 9.33× |
| 2018-12-31 | $1.20B | $179.49M | $420.15M | $662.80M | $18.76M | $24.07M | $59.71M | (m) | 6.69× |
| 2018-09-30 | $1.34B | $121.50M | $316.61M | $905.22M | $3.36M | $11.08M | $21.77M | (m) | 11.05× |
| 2018-06-30 | $1.50B | $113.66M | $361.46M | $1.07B | (m) | (m) | $11.99M | (m) | 13.22× |
| 2018-03-31 | $1.69B | $115.38M | $396.15M | $1.17B | (m) | (m) | $13.21M | (m) | 14.61× |
| 2017-12-31 | $1.76B | $144.25M | $645.36M | $1.05B | $34.00M | (m) | $28.36M | (m) | 12.23× |
| 2017-09-30 | $993.37M | $101.05M | $202.04M | $746.25M | (m) | (m) | $9.24M | (m) | 9.83× |
| 2017-06-30 | $960.71M | $108.73M | $408.67M | $514.60M | (m) | (m) | $23.17M | (m) | 8.84× |
| 2017-03-31 | $597.19M | $95.79M | $171.08M | $385.84M | (m) | (m) | $25.37M | (m) | 6.23× |
| 2016-12-31 | $671.88M | $131.70M | $193.62M | $424.19M | (m) | (m) | $54.47M | (m) | 5.10× |
| 2016-09-30 | $747.56M | $81.76M | $168.48M | $531.04M | (m) | (m) | $23.14M | (m) | 9.14× |
| 2016-06-30 | $888.07M | $70.58M | $271.08M | $571.99M | (m) | (m) | $12.82M | (m) | 12.58× |
| 2016-03-31 | $1.05B | $66.37M | $231.28M | $748.42M | (m) | (m) | $17.44M | (m) | 15.82× |
| 2015-12-31 | $1.11B | $62.10M | $180.90M | $848.22M | (m) | (m) | $16.79M | (m) | 17.80× |
| 2015-09-30 | $1.04B | $57.11M | $149.22M | $828.43M | (m) | (m) | $14.27M | (m) | 18.24× |
| 2015-06-30 | $1.03B | $66.60M | $151.26M | $788.74M | (m) | (m) | $15.71M | (m) | 15.45× |
| 2015-03-31 | $1.09B | $80.69M | $306.58M | $660.40M | (m) | (m) | $15.49M | (m) | 13.51× |
| 2014-12-31 | $746.37M | $95.33M | $75.18M | $526.93M | (m) | (m) | $15.11M | (m) | 7.83× |
| 2014-09-30 | $643.02M | $56.85M | $82.72M | $507.93M | (m) | (m) | $5.20M | (m) | 11.31× |
| 2014-06-30 | $665.12M | $53.74M | $80.73M | $524.59M | (m) | (m) | $6.17M | (m) | 12.38× |
| 2014-03-31 | $674.06M | $83.83M | $350.59M | $314.90M | (m) | (m) | $5.04M | (m) | 8.04× |
| 2013-12-31 | $254.03M | $53.86M | $53.17M | $192.70M | (m) | (m) | $5.90M | (m) | 4.72× |
| 2013-09-30 | $199.16M | $54.90M | $11.84M | $181.94M | (m) | (m) | $2.73M | (m) | 3.63× |
| 2013-06-30 | $214.36M | $53.07M | $24.98M | $184.72M | (m) | (m) | $4.53M | (m) | 4.04× |
| 2013-03-31 | $240.11M | $49.75M | $97.80M | $138.21M | (m) | (m) | $3.10M | (m) | 4.83× |
| 2012-12-31 | $125.56M | $48.34M | $51.41M | $71.41M | (m) | (m) | $4.42M | (m) | 2.60× |
| 2012-09-30 | $235.93M | $54.76M | $75.84M | $152.50M | (m) | (m) | $5.09M | (m) | 4.31× |
| 2012-06-30 | $240.34M | $57.06M | $48.27M | $180.75M | (m) | (m) | $5.52M | (m) | 4.21× |
| 2012-03-31 | $208.54M | $66.64M | $61.74M | $137.36M | (m) | (m) | $4.34M | (m) | 3.13× |
| 2011-12-31 | $152.03M | $80.99M | $70.23M | $76.17M | (m) | (m) | $5.80M | (m) | 1.88× |
| 2011-09-30 | $179.96M | $93.93M | $74.34M | $98.69M | (m) | (m) | $5.49M | (m) | 1.92× |
| 2011-06-30 | $224.33M | $100.53M | $67.11M | $150.84M | (m) | (m) | $7.95M | (m) | 2.23× |
| 2011-03-31 | $250.71M | $99.34M | $90.59M | $154.05M | (m) | (m) | $5.80M | (m) | 2.52× |
| 2010-12-31 | $254.14M | $102.05M | $74.60M | $158.53M | (m) | (m) | $9.31M | (m) | 2.49× |
| 2010-09-30 | $244.62M | $99.43M | $46.88M | $184.49M | (m) | (m) | $6.56M | (m) | 2.46× |
| 2010-06-30 | $273.51M | $102.03M | $66.18M | $193.01M | (m) | (m) | $10.40M | (m) | 2.68× |
| 2009-12-31 | $293.53M | $110.73M | $137.47M | $143.93M | (m) | (m) | $12.49M | (m) | 2.65× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |